I. Introduction {#s2}
===============

Early biologists viewed cellular proteins as essentially stable constituents subjected to only minor "wear and tear." The widely accepted theory was that dietary proteins functioned primarily as energy, providing fuel for the body. Rudolf Schoenheimer and colleagues challenged that notion in the late 1930s, using stable isotopes to show that trace dietary amino acids rapidly incorporated into tissue proteins ([@B212]) and that these proteins are in a dynamic state of synthesis and degradation ([@B211]). Today we understand that all intracellular proteins are continually "turning over" (i.e., they are being hydrolyzed into their constituent amino acids and replaced via de novo synthesis). Individual proteins are degraded at different rates, varying from minutes for certain regulatory enzymes to days for myosin heavy chains in cardiac muscle and to months for hemoglobin in erythrocytes ([@B147]). Although cytosolic proteins can be degraded in lysosomes (via chaperone-mediated autophagy and macroautophagy), the majority are degraded by the proteasome ([@B92]).

The discovery of a special class of cytoplasmic granules containing acid hydrolases in the 1950s ([@B62]; [@B9]), called lysosomes ([@B63]), was an important step forward in understanding intracellular protein breakdown. Breakdown of endogenous (autophagy) and exogenous (heterophagy) material was believed to occur in lysosomes, the "intracellular digestive system" ([@B64]). Because peptide hydrolysis is an exergonic (i.e., downhill) reaction, the discovery of ATP-dependent protein breakdown in mammalian ([@B217]) cells was unexpected. [@B217] suggested "the possible existence of two (or more) mechanisms of protein breakdown, one hydrolytic, the other energy-requiring." Subsequent work over the next 2 decades firmly established that both rates of protein synthesis and degradation determine the cellular protein concentration as well as the wide variability of protein half-lives ([@B206]; [@B207]; [@B261]).

Studies in the 1970s supported the prediction of a new selective degradation pathway that accounted for the wide distribution of protein half-lives ([@B93]; [@B97]; Poole et al., 1976). Interestingly, cytosolic proteins synthesized with structural analogs of normal amino acids are rapidly degraded within the cell ([@B93]; [@B139]). These seminal observations added another layer of selectivity in which the inherent stability of each protein also determines the degradation rate, presumably to prevent the accumulation of abnormal proteins. However, the mechanism of selectivity remained a mystery. ATP was found to be essential for protein catabolism, but it was unknown whether a proteolytic step was directly dependent on ATP or whether it required some additional reactions ([@B98]). Selective and ATP-dependent protein degradation was not congruent with the notion of the lysosome as the key player in protein breakdown. What could be responsible for this exquisitely controlled protein degradation? [@B82] identified a novel, soluble, ATP-dependent proteolytic system that was independent from the lysosome. The importance of the soluble degradation system was emphasized when Rechsteiner and colleagues showed that most intracellular proteins are degraded in the cytosol, not the lysosome ([@B30]).

[@B253] purified a 700-kDa "multicatalytic proteinase complex" (later shown to be the 20S proteasome). Unlike all other known proteases, this new protease complex could cleave peptides after basic, acidic, or hydrophobic residues, suggesting that it contained multiple distinct active sites ([@B253], [@B254]). Electron micrographs revealed the complex to be a 700-kDa stacked "donut" ring structure ([@B232]). Due to their critical roles in intracellular protein breakdown, these protease complexes were collectively renamed "proteasomes" ([@B12]). Analogous protease complexes of equivalent size, shape, polypeptide composition, and proteolytic activities have since been identified across all three domains of life ([@B232]; [@B94]).

The next major advancement in the field came with the discovery of ubiquitin, a small approximately 8-kDa protein with a big role in protein degradation. Aaron Ciechanover and colleagues identified a small heat-stable protein, ubiquitin, covalently conjugated to target substrates ([@B56]) in an ATP-dependent manner ([@B55]; [@B255]). This led to the proposed model in which protein-substrate modification by several ubiquitin moieties targets it for degradation by a downstream, as-yet-unidentified protease that cannot recognize the unmodified substrate ([@B112]). It was later shown that some nonubiquitin proteins are also degraded in an ATP-dependent manner ([@B231]). Rechsteiner's group later went on to purify the ATP-dependent 26S proteasome responsible for ubiquitin conjugate degradation ([@B118], [@B119]).

Avram Hershko, Aaron Ciechanover, and Irwin Rose characterized the system of ubiquitin conjugation and its role in marking proteins for degradation ([@B114]), an achievement that earned them the Nobel Prize in Chemistry (2004) ([@B50]). Attachment of poly-ubiquitin chains to specific proteins selects them for proteasome-mediated degradation ([Fig. 1A](#F1){ref-type="fig"}). Targeting proteins for degradation requires three enzymatic components to link chains of ubiquitin onto selected protein substrates. E1 (ubiquitin-activating enzyme) and E2s (ubiquitin-carrier or conjugating proteins) prepare ubiquitin for conjugation. The E3 (ubiquitin-protein ligase) enzymes control substrate specificity, recognizing substrate degradation signals and catalyzing the transfer of activated ubiquitin to the substrate ([@B53]; [@B114]). Eukaryotic cells contain hundreds of E3 ligases, allowing the cell to precisely control ubiquitination and degradation of individual proteins ([@B51]). Ubiquitin conjugation is necessary for cell viability ([@B54]; [@B86]) and activity of the ubiquitin pathway is greatly increased in cells making abnormal proteins ([@B113]).

![The ubiquitin proteasome pathway. (A) Simplified model of the ubiquitin conjugation system. (B) Primary steps involved in ubiquitinated substrate processing by the 26S proteasome.](pr.117.015370f1){#F1}

During the past 20 years, investigators have established the critical role of the ubiquitin proteasome system (UPS) in cell cycle progression ([@B111]; [@B182]; [@B19]), transcriptional regulation, genome integrity, apoptosis, immune responses ([@B24]), and the pathogenesis of many human diseases ([@B92]; [@B204]). With respect to disease, the proteasome is particularly important for maintaining cellular protein homeostasis (i.e., proteostasis). When the efficiency of proteostasis systems declines, misfolded and damaged proteins aggregate to toxic levels within the cell, potentially giving rise to many neurodegenerative diseases ([@B146]; [@B165]). Too much of a good thing can be just as detrimental. Cancer cells rely on robust proteasome activity for degrading tumor suppressors and cell cycle checkpoint inhibitors necessary for rapid cell division ([@B77]). Numerous processes rely on finely tuned proteasome function, making it a crucial target for therapeutic intervention in many diseases, including neurodegenerative diseases, cystic fibrosis, atherosclerosis, autoimmune diseases, diabetes, and cancer ([@B209]). In 2003, bortezomib (Velcade; Takeda Pharmaceuticals, Cambridge, MA) became the first U.S. Food and Drug Administration (FDA)--approved proteasome inhibitor as a third-line treatment of multiple myeloma (MM).

In this review, we first discuss the structure, function, and regulation of the proteasome. Then we discuss the classes and mechanisms of action of proteasome inhibitors. Next, we summarize commonly used in vitro and in vivo techniques for studying proteasome activity and inhibition, followed by a review of currently FDA-approved proteasome inhibitors as well as novel inhibitors undergoing clinical and preclinical trials. Finally, we discuss how pharmacological activation of the proteasome could produce novel therapeutics to treat neurodegenerative disease.

II. Proteasome Structure and Function {#s3}
=====================================

A. Proteasome Structure and Activity {#s4}
------------------------------------

The 26S proteasome is a 2.4-MDa molecular machine that makes up nearly 2% of total cellular protein ([@B135]). It is composed of a 20S proteasome core particle capped on one or both ends by the 19S regulatory particle ([Fig. 1B](#F1){ref-type="fig"}). It degrades proteins by a multistep process; the 19S regulatory particle binds ubiquitinated substrates, opens a substrate entry gate in 20S ([@B68]; [@B1]), and unfolds its substrates by linearly translocating them into the 20S catalytic chamber, where they are degraded to peptides ([@B69]; [@B246]). Numerous studies over the past 2 decades have developed our present understanding of proteasome structure and function. The first 20S core particle was crystalized in the late 1990s ([@B100]). Since then, hundreds of 20S structures, complexed with regulators or inhibitors, have been solved.

Eukaryotic proteasomes contain four stacked heteroheptameric rings arranged in a *α*~7~-*β*~7~-*β*~7~-*α*~7~ fashion ([@B100]). The amino (N) termini of the *α* subunits form a "gate," folding over the 13-Å central pore and occluding access to the proteolytic sites located on the *β*-subunit lumen ([@B99]). Passage through this gate is the rate-limiting step and prevents unregulated protein degradation ([@B141]). The *α*N-terminal tails are highly conserved, containing a tyrosine-aspartate-arginine (YDR) motif that forms salt bridges with neighboring tails that obstruct the 13-Å entry pore. The *α*3 N terminus is the lynchpin, critical for stabilizing the closed-gate confirmation ([@B141]). Note that the purified latent 20S proteasome still exhibits a degree of peptidase activity due to stochastic conformational fluctuations within the N termini ([@B196]; [@B202]). Interestingly, deletion of the first eight *α*3 residues (*α*3∆N-20S) sufficiently destabilizes the closed-gate conformation and accelerates the entry and degradation of peptides ([@B141]). *α*3∆N-20S crystallographic structures show that the remaining N termini are disordered, resulting in a constitutively open gate ([@B141]). Wild-type 20S proteasome activity is similarly accelerated when bound to a proteasome activator (e.g., 19S/PA700, 11S/PA28, Blm10/PA200) ([@B85]). Proteasome activators bind to a free end of the *α*-subunit ring and "open" the gate by distinct mechanisms that are discussed in detail below.

### *1. Active Sites of the 20S Proteasome* {#s5}

The eukaryotic 20S proteasome contains six proteolytically active *β* subunits, three on each *β* ring, that exhibit different substrate preferences ([Fig. 2, A and B](#F2){ref-type="fig"}). The various substrate binding pockets determine active site specificity like classic proteases but with more complexities. The binding pockets themselves are formed by specific interactions between the catalytic subunit and the neighboring *β* subunit ([@B32]). As a result, the proteasome is not simply a complex of independent proteases but is a unique multicatalytic enzyme functioning only when wholly intact. The chymotrypsin-like site (*β*5) preferentially cleaves after hydrophobic residues, the trypsin-like site (*β*2) preferentially cleaves after basic residues, and the caspase-like site (*β*1) preferentially cleaves after acidic residues ([@B11]; [@B246]). Despite their names, these sites do not share the catalytic mechanisms of their namesakes and their substrate preferences are much broader than the names imply ([@B135]). Multiple catalytic sites with varying specificities advantageously allow for the rapid and processive degradation of cellular proteins.

![Proteasome structure and function. (A) Structures (PDB 4r3o) and cartoon representation of 20S proteasome, highlighting the different *β*-subunit combinations found in tissue-specific proteasomes discussed in the text. (B) Structure of the 26S proteasome in complex with Ubp6 (PDB 5a5b). A cross-section of 20S proteasome reveals the C terminus of Rpt5 ATPase (dark orange) positioned in the inter-*α*-subunit pocket (asterisk). Proteolytic sites are marked with yellow stars. Labeled 19S subunits are discussed in the text. (C) 20S proteasomes (blue and gray) complexed with regulatory caps: PA28 homolog PA26 (PDB 1fnt), 19S (PDB 5gjr), and PA200 yeast homolog Blm10 (PDB 4v7o). 19S ATPases are dark orange, and non-ATPase subunits are light orange. PDB, Protein Data Bank.](pr.117.015370f2){#F2}

All proteasome active sites use an N-terminal threonine nucleophile. Enzyme inhibitor and site-directed mutagenesis studies compose much of what we know about the proteasome's unusual catalytic mechanism ([@B102]). Although proteasomes lack the classic catalytic triad found in cysteine and serine proteases, the proteasome's sensitivity to peptide aldehyde inhibitors suggests a similar catalytic mechanism ([@B102]). Accordingly, the crystal structure of 20S bound to the peptide aldehyde Ac-Leu-Leu-nLeu-al (ALLN) reveals a hemiacetyl bond between the *β*-subunit N-terminal threonine hydroxyl groups ([@B102]). Proteasome inhibitors (lactacystin, vinyl sulfones, and epoxyketones) are often found to covalently modify this threonine. As expected, mutation to a serine residue retains significant activity, whereas mutation to an alanine residue completely abolishes activity ([@B102]).

### *2. Specialized Catalytic Subunits* {#s6}

Some cell types express *β* subunits with modified catalytic sites under certain conditions. Immune cells constitutively express alternative catalytic subunits (*β*1i/LMP2, *β*2i/MECL-1, and *β*5i/LMP7) that are preferentially incorporated into the 20S proteasome de novo in place of the constitutive *β*1 (*β*1c), *β*2 (*β*2c), and *β*5 (*β*5c) subunits, forming the immunoproteasome ([@B230]) ([Fig. 2A](#F2){ref-type="fig"}). The immunoproteasome is also expressed in nonhematopoietic cells when exposed to interferon (IFN)-*γ* or tumor necrosis factor-*α* ([@B230]). To our knowledge the main purpose of the immunoproteasome is to enhance ligand generation for major histocompatibility complex class I (MHC-I) molecules ([@B198]) that allow for immune surveillance ([@B240]). How do these immune subunits do this? These subunits use the same catalytic mechanism as their constitutively expressed counterparts but they have different cleavage preferences due to changes in substrate binding pockets ([@B89]; [@B102]). The most striking difference between constitutive and immunoproteasomes is the *β*1i subunit, which lacks caspase-like activity but instead cleaves after hydrophobic residues ([@B102]). This is a crucial difference because only MHC-I molecules with tightly bound ligands are expressed on the cell surface. Tight class I binding requires ligands eight to nine amino acids in length with either a hydrophobic or basic anchor residue at the C terminus. Ligands with acidic C termini are not accepted ([@B83]; [@B138]). Thus, the immunoproteasome facilitates the production of peptides suitable for MHC-I presentation ([@B198]).

Human thymus cortical epithelial cells express a thymic-specific catalytic subunit, *β*5t; *β*5t, *β*1i, and *β*2i together form the thymoproteasome ([@B174]) ([Fig. 1A](#F1){ref-type="fig"}). The thymoproteasome is essential for T-lymphocyte positive selection. Compared with *β*5c and *β*5i, *β*5t has weak chymotrypsin-like activity; thus, it is speculated that thymoproteasomes facilitate the low-affinity MHC-I molecule ligand production necessary for positive selection ([@B174]). Further details on unique functions of tissue-specific proteasomes can be found in [@B138].

### *3. Proteasome Regulatory Caps and Their Diverse Biologic Roles* {#s7}

Regulation of gate opening in the 20S proteasome is an important aspect of proteasome function; as such, the cell has evolved many different proteasomal regulators that control 20S gate opening ([@B85]). The most well known regulator is 19S (PA700), a component of the 26S proteasome. The 26S proteasome is a structurally dynamic complex, adopting large-scale conformational changes around the central axis during the ATP-dependent processing of substrates ([@B21]; [@B164]; [@B219]; [@B17]). These structural changes appear to be necessary for substrate protein unfolding and injection into the 20S core particle.

Ubiquitin-dependent degradation requires several steps: 1) substrate binding and commitment, 2) 20S gate opening, 3) substrate unfolding and translocation, and 4) deubiquitination ([Fig. 2B](#F2){ref-type="fig"}). First, the 19S regulatory particle has three integral subunits that serve as substrate receptors: Rpn1, Rpn10, and Rpn13. These substrate receptors reversibly associate with ubiquitin, and have only low affinity for mono-ubiquitin ([@B65]). The multiplicity of ubiquitin receptors coupled with a variety of shuttling factors, such as proteins that have a ubiquitin-like (UBL) domain and a ubiquitin-associating domain, allows the 26S proteasome to recognize and degrade many types of ubiquitin conjugates ([@B57]). Substrate binding to the ubiquitin receptors induces a conformational change aligning the 19S ATPase translocation channel directly over the 20S gate ([@B17]), induces gate opening, and stimulates ATP hydrolysis ([@B183], [@B184]). Substrate commitment requires a loosely folded region of the protein (e.g., unstructured initiation site) to insert into the ATPase ring in an ATP-dependent manner ([@B185]). Tyrosine pore loops inside the ATPases "grip" the substrate and this tight association enables the processive process of substrate unfolding and translocation into the 20S core ([@B57]; [@B224]). Second, the six ATPase subunits (Rpt1--6) form a ring at the bottom of the 19S complex with their C termini inserting into the 20S *α*-subunit intersubunit pockets ([@B192]). 19S-dependent gate opening requires ATPase C-terminal hydrophobic-tyrosine-any residue (HbYX) motif binding to intersubunit pockets (between the *α* subunits) on top of the 20S ([@B260]). Binding of the 19S C termini to the 20S is thought to induce a conformational change in the *α* subunits, opening the gate ([@B192]). The exact mechanisms behind the 26S HbYX-motif gate opening in human 26S proteasomes are not clear. However, binding of an HbYX-motif peptide (the last eight residues of Rpt5) is sufficient to allosterically induce conformational changes in the 20S *α* subunit and open the gate ([@B222]). Third, the six ATPase subunits power processive unfolding and translocation of substrates into the 20S core coupled with ATP hydrolysis ([@B221]; [@B22]). Fourth, Rpn11 is the integral proteasome-associated deubiquitinase (DUB) enzyme of the 19S complex. Rpn11 is positioned directly above the translocation channel when substrate is committed for degradation and removes the entire ubiquitin chain as proteins are translocated ([@B65]). Two other DUBs are transiently associated with proteasomes (Usp14 and Uch37) and they can trim substrate ubiquitin chains prior to the committed step, rescuing the substrate from degradation ([@B65]). Proteasome-associated DUBs are discussed in section VI.

In addition to 19S, there are two other proteasome gate activator families, 11S and PA200/Blm10, neither of which contains unfoldase activity or requires ATP ([Fig. 2C](#F2){ref-type="fig"}). Higher eukaryotes express three 11S regulatory subunits: PA28*α*,*β*,*γ* (also known as REG*α*,*β*,*γ*) ([@B126]; [@B194]). PA28*αβ* forms an inducible heteroheptamer that is primarily located in the cytoplasm. In contrast, PA28*γ* forms a homoheptamer that is constitutively expressed in the nucleus ([@B15]; [@B85]). The biologic roles of these regulators remain relatively mysterious. However, both forms of PA28 regulators show increased expression after acute oxidative stress in cells, suggesting that both play a significant role in oxidized protein degradation ([@B186]). In addition, IFN-*γ* increases PA28*αβ* expression, oxidized protein degradation capacity ([@B186]), and MHC-I ligand generation.

PA200 (Blm10 in yeast) plays a role in spermatogenesis ([@B131]), response to DNA repair ([@B239]), glutamine homeostasis ([@B31]), and mitochondrial inheritance ([@B203]), although molecular details behind many of these functions are not clear. The crystal structure of yeast Blm10-20S shows that Blm10 forms a large HEAT repeat-like solenoid in a 1.5 superhelical turn, forming a dome that caps the ends of the 20S proteasome ([@B203]). One C-terminal HbYX motif binds between the *α*5- and *α*6-intersubunit pocket and facilitates gate opening ([@B177]; [@B210]). As with the 19S Rpt5 subunit, an eight-amino-acid Blm10 C-terminal fragment (Blm-pep) induces gate opening in purified 20S proteasomes ([@B257]). The Blm-pep--bound 20S crystal structure closely resembles the bound HbYX in the full-length Blm10 structure. PA200/Blm10-containing proteasomes specifically catalyze the acetylation-dependent, but not polyubiquitination-dependent, core histone degradation during somatic DNA damage response and spermatogenesis ([@B189]). During spermatogenesis, the spermatoproteasome (formed by PA200, 20S, *β*1i, *β*2i, *β*5i, and the human testis-specific *α*4~s~) degrades core histones and is required for proper sperm maturation and viability ([@B189]). The existence of interchangeable proteasome subunits highlights the cell's repertoire of proteasome complexes tailored for specific cellular roles.

B. Proteasome-Dependent Cellular Processes {#s8}
------------------------------------------

Proteasome function is essential to cellular homeostasis. In addition to maintaining proteostasis, the proteasome plays a key role in regulating many physiologic processes. Four major areas not previously discussed include cell cycle regulation, nuclear factor-*κ*B (NF-*κ*B) activation, neuronal function, and endoplasmic reticulum (ER)--associated protein degradation ([Fig. 3](#F3){ref-type="fig"}).

![Examples of cellular functions that depend on proteasome function. Important pathways dependent on proteasome function and exemplar substrates. Bax, bcl-2-like protein 4; Bim, bcl-2-like protein 11; Cdk, cyclin-dependent kinase; Drp1, dynamin-1-like protein; ERAD, endoplasmic-reticulum-associated protein degradation; E2F-1, target of retinoblastoma protein; Fis1, mitochondrial fission 1 protein; GABA, gamma-aminobutyric acid; JNK, C-Jun-amino-terminal kinase; Mfn, mitofusin; MHC-I, major histocompatibility complex-I; Miro, mitochondrial Rho GTPase; NF-*κ*B, nuclear factor--*κ*B; PKA, protein kinase A; PSD-95, postsynaptic density protein 95; Topo II, type II topoisomerase; Wnt, wingless-type.](pr.117.015370f3){#F3}

### 1. Cell Cycle {#s9}

The proteasome degrades many cell cycle regulatory proteins that typically have short half-lives (e.g., cyclin B1, p21, p27) and tumor suppressors (e.g., p53) promoting cycle progression ([@B73]; [@B160]; [@B6]; [@B259]; [@B216]). Not surprisingly, most cancers heavily rely on proteasome activity and are more susceptible to proteasome inhibition than normal cells ([@B79]; [@B180]; [@B133]). Proteasome inhibition in cancer is discussed in section IV.

### 2. Nuclear Factor-κB Activation {#s10}

The NF-*κ*B transcription factors (NF-*κ*B and Rel proteins) regulate expression of genes involved in innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. In cancer cells, NF-*κ*B is critically involved in the expression of the antiapoptotic IAP family of genes as well as BCL-2 prosurvival genes ([@B249]; [@B263]; [@B43]).

Canonical and noncanonical NF-*κ*B activation requires proteasome-mediated degradation of regulatory elements for transcriptional activation. In the unstimulated state, the inhibitory I*κ*B subunits bind and sequester NF-*κ*B/Rel complexes in the cytoplasm ([@B16]). In canonical pathway activation, proinflammmatory cytokines activate the I*κ*B kinase (IKK) complex (IKK*β*, IKK*α*, and NF-*κ*B essential modulator), which phosphorylates I*κ*B, leading to I*κ*B ubiquitination and proteasomal degradation ([@B46]; [@B205]; [@B225]; [@B256]), freeing NF-*κ*B/RelA complexes. Freed NF-*κ*B/RelA complexes translocate to the nucleus, where they (either alone in or combination with other transcription factors) induce target gene expression. In the noncanonical pathway, NF-*κ*B--p100/RelB complexes are inactive in the cytoplasm. Signaling activates the NF-*κ*B--inducing kinase, which activates IKK*α* complexes that phosphorylate NF-*κ*B2--p100 C-terminal residues. Phosphorylated NF*κ*B is ubiquitinated and processed by the proteasome into NF-*κ*B2--p52, which is transcriptionally competent. Such processing by the proteasome is remarkable since it requires the initiation of protein degradation, followed by termination of degradation at a specific domain, demonstrating exquisite control over degradation. After processing, NF-*κ*B2--p52 translocates to the nucleus and induces target gene expression. NF-*κ*B is a prosurvival pathway and is upregulated in many cancers and inflammatory diseases ([@B248]). Given the indispensable role of proteasome function in activating this pathway, proteasome inhibition is a valid therapeutic target. The role of NF-*κ*B in cancer pathology is discussed further in section V.

### 3. Neuronal Function {#s11}

Maintaining proteostasis in neurons is especially important due to their complex architecture, long lifespan, and inability to dilute aggregate load through cell division ([@B229]). Importantly, the UPS is critical for normal functioning of neuronal synapses, including synaptic protein turnover, plasticity, and long-term memory formation, which rely on tightly controlled changes in the proteome ([@B87]; [@B229]; [@B13]; [@B75]). In addition to the intracellular proteasomes, [@B193] identified a mammalian nervous system--specific membrane-associated proteasome complex that rapidly modulates neuronal function. This proteasome complex degrades intracellular proteins and releases the products into the synaptic cleft, where they stimulate postsynaptic *N*-methyl-[d]{.smallcaps}-aspartate receptor--dependent neuronal signaling, a process important for regulating synaptic function.

The accumulation of aggregation-prone proteins is a hallmark of neurodegenerative disease commonly accompanied by loss of proteostasis and progressive death of neurons ([@B214]; [@B201]; [@B36]). It is established that proteasome function is decreased in neurodegenerative diseases, and its impairment is implicated in the development of many neurodegenerative diseases, including Alzheimer, Parkinson, and Huntington diseases ([@B128]; [@B167]; [@B52]; [@B201]; [@B178]). To highlight this point, brain region--specific proteasome inhibition closely mirrors the neuropathology and clinical hallmarks of neurodegenerative diseases ([@B166], [@B168]; [@B23]; [@B153]). The importance of targeting the proteasome for potential neurodegenerative disease therapy is discussed in section VI.

### 4. Endoplasmic Reticulum--Associated Protein Degradation and the Unfolded Protein Response {#s12}

Secretory proteins and most integral membrane proteins are synthesized and enter the ER lumen for proper folding and covalent modifications. The endoplasmic reticulum--associated protein degradation (ERAD) pathway is an evolutionarily conserved process that discards misfolded ER proteins ([@B258]). Three different ERAD pathways (ERAD-L, ERAD-M, and ERAD-C) are used for degrading misfolded ER proteins, depending on whether their misfolded domain is localized in the ER lumen, within the membrane, or on the cytosolic side of the ER membrane, respectively ([@B122]; [@B244]; [@B40]). A fourth pathway is responsible for misfolded protein removal from the inner nuclear membrane ([@B88]; [@B130]). Each pathway involves distinct ubiquitin ligases and cofactors, although it is unclear how proteins are targets to each pathway. ERAD substrates from all pathways are retrotranslocated to the cytosolic side of the membrane ([@B258]). With the help of ubiquitination machinery and the Cdc48/p97 ATPase complex, the substrates are extracted from the membrane and delivered to the 26S proteasome for degradation ([@B20]; [@B35]; [@B124]; [@B191]). Proteasome inhibition stalls ERAD and causes misfolded proteins to accumulate within the ER. In response, the cell activates a highly conserved signaling pathway called the unfolded protein response (UPR) ([@B236]). Multiple physiologic conditions also lead to accumulation of misfolded proteins in the ER and subsequent UPR activation, including hypoxia, glucose deprivation, oxidative stress, and mutations in certain secretory proteins ([@B236]). UPR activation regulates the gene expression involved in protein folding (e.g., chaperones) and ERAD and decreases protein translation into the ER in an attempt to restore ER homeostasis ([@B235]). The UPR initially performs a protective role in the cell. However, prolonged ER stress and UPR activation eventually leads to cell death ([@B235]). [@B258] recently published an extensive review discussing the molecular mechanisms of ERAD and associated protein degradation.

III. Development of Proteasome Inhibitors {#s13}
=========================================

A. The Rise of Proteasome Inhibitors {#s14}
------------------------------------

Our understanding of the importance of the UPS for biologic functions and processes rapidly advanced with the introduction of the first proteasome inhibitors ([@B199]). These valuable tools allowed researchers to interrogate proteasome function in complex cellular systems and tissues and greatly advanced our understanding of many aspects of cell regulation, disease mechanisms, and immune surveillance ([@B198]). Perhaps the most clinically important developments to come from the early proteasome inhibitor studies were advancements in understanding the regulation of NF-*κ*B and its key role in the pathogenesis of many inflammatory and neoplastic diseases ([@B181]; [@B94]). The first proteasome inhibitors were simple hydrophobic peptide aldehydes (analogs of serine protease inhibitors) designed to mimic the preferred substrates of the proteasome's chymotrypsin-like site (*β*5) and inhibit it ([@B94]). The tripeptide aldehyde, MG-132 (carbobenzyl-Leu-Leu-Leu-aldehyde), is still the most widely used proteasome inhibitor in scientific research because it is potent, inexpensive, and quickly reversible ([@B94]). Given the indispensable role of the proteasome in the NF-*κ*B pathway, proteasome inhibitors showed therapeutic potential for the treatment of some human diseases, yet it was also appreciated that complete proteasome inhibition would lead to cell death ([@B94]).

Researchers hypothesized that partial and reversible inhibition of the proteasome might be beneficial in killing neoplastic cells because they lack many of the checkpoint mechanisms that protect normal cells from apoptosis ([@B2]; [@B94]). Accordingly, proteasome inhibitors were preferentially toxic to transformed and patient-derived malignant cell cultures rather than their nontransformed and healthy counterparts ([@B162]; [@B2]). Aldehyde proteasome inhibitors (e.g., MG-132) had limited therapeutic potential in humans due to off-target effects (e.g., inhibition of cathepsin B and calpains) and poor metabolic stability ([@B5]). With MG-132 as a lead compound, a team of medicinal chemists led by Julian Adams synthesized the dipeptide boronic acid PS-341 (Pyz-Phe-boroLeu), a slowly reversible inhibitor of the *β*5 active site (with some activity toward the *β*2 active site). PS-341 proved to be a potent and selective proteasome inhibitor, demonstrating therapeutic activity in preclinical models of inflammatory diseases and human cancers ([@B7]; [@B162]; [@B2]). PS-341 entered phase I clinical trials, in which remarkably one patient with MM showed a complete response to PS-341 treatment ([@B2]). MM is an incurable plasma cell malignancy; at that time, patients had a poor prognosis due to lack of effective treatment options, making the complete response to PS-341 a dramatic clinical breakthrough ([@B94]). PS-341 progressed to phase II trials for MM and chronic lymphoid leukemia. Due to the remarkable success of PS-341 in phase II trials, the FDA approved PS-341 (later renamed bortezomib and marketed as Velcade) ([Fig. 4A](#F4){ref-type="fig"}) as a third-line treatment for relapsed and refractory multiple myeloma (RRMM) in 2003 ([@B94]). Bortezomib revolutionized the treatment of MM, and today bortezomib is approved for use as a first-line therapy for MM and mantle cell lymphoma.

![Proteasome inhibitors and the *β*5 binding site. (A) Chemical structures of proteasome inhibitors that are FDA approved and/or are in clinical trials with pharmacophores shown in red. For ixazomib, the orally bioavailable prodrug (MLN9708) is shown, with the biologically active metabolite (MLN2238) highlighted in black and red for clarity. (B) X-ray crystallography structures of human 20S proteasomes in complex with carfilzomib (PDB 4r67), bortezomib (PDB 5lf3), and ixazomib (PDB 5lf7); yeast 20S in complex with marizomib (PDB 2fak); and the cryo-EM structure of human 26S in complex with oprozomib (PDB 5m32). PDB, Protein Data Bank.](pr.117.015370f4){#F4}

Despite its clinical success in treating hematologic diseases, bortezomib therapy is associated with a high rate of resistance (primary or secondary) and serious dose-limiting toxicity, which require reduction or discontinuation of the drug ([@B95]). Advances in proteasome inhibitor chemistry and a better understanding of the proteasome's unique catalytic mechanism have led to the development of second-generation proteasome inhibitors with improved pharmacokinetics compared with bortezomib ([@B96]). The mechanisms of available proteasome inhibitors and their uses in research and clinical settings are discussed in the following sections.

B. Chemical Classes of Proteasome Inhibitors {#s15}
--------------------------------------------

There are several classes of proteasome inhibitors. Like the majority of protease inhibitors, most proteasome inhibitors are short peptides designed to fit into the substrate binding site on the catalytic subunit. The activity of proteasome inhibitors depends on the pharmacophore warhead at the C terminus, which reacts with the active site threonine nucleophile to form reversible or irreversible covalent adducts ([@B135]). Although the proteasome has three types of catalytic sites, inhibition of all three is not required to significantly affect protein degradation ([@B134]). Specific *β*1 or *β*2 inhibition does not have a significant effect on overall protein breakdown; however, *β*5 inhibition results in significantly reduced protein breakdown ([@B134]). Consequently, most proteasome inhibitors target the *β*5 site, although they often have some lesser activity against *β*1 and/or *β*2 ([@B134]).

### 1. Peptide Aldehydes {#s16}

Based on the well characterized serine and cysteine protease inhibitors, peptide aldehydes (e.g., MG-132) were the first synthesized proteasome inhibitors. MG-132 is cell permeable and is a reversible proteasome inhibitor, which makes it a valuable research tool. Because MG-132 has slow binding and fast dissociation kinetics ([@B135]), the effects of MG-132 proteasome inhibition on cultured cells are quickly reversed by switching to inhibitor-free media. The low cost and rapid reversibility make MG-132 the most used proteasome inhibitor for research ([@B94]). However, there are several limitations to MG-132. First, MG-132 in cell culture media is rapidly oxidized into an inactive acid ([@B135]). For long cell culture experiments, MG-132--containing media should be replaced daily. Second, as with other peptide aldehydes, MG-132 also inhibits (albeit with much lower affinity) calpains and cathepsins ([@B135]); therefore, it is necessary to perform control experiments to confirm that the observed effects are due to proteasome inhibition. Proteasome involvement can be verified using a more selective proteasome inhibitor (e.g., epoxomicin, boronates, and lactacystin), although these compounds may be cost prohibitive for routine studies or screens. In addition, inhibitors that specifically block other proteases, such as E-64 \[(2*S*,3*S*)-3-\[\[(2*S*)-1-\[4-(diaminomethylideneamino)butylamino\]-4-methyl-1-oxopentan-2-yl\]carbamoyl\]oxirane-2-carboxylic acid\] for calpains, but not the proteasome can be used to confirm that the observed effect is not due to off-target inhibition of another protease.

### 2. Peptide Boronates {#s17}

Peptide boronates are significantly more potent proteasome inhibitors compared with peptide aldehydes. Like peptide aldehydes, peptide boronates form a tetrahedral adduct with the active site threonine but their dissociation rate is much slower, making boronates practically irreversible over hour-scale time courses ([@B135]). MG-262 (Cbz-Leu-Leu-Leu-B(OH)2), the boronate analogue of MG-132, is 100-fold more potent than its aldehyde counterpart ([@B135]). In addition, peptide boronates are not oxidized into inactive forms like MG-132, making them more stable in vivo ([@B135]). The boronate warhead cannot react with active site cysteines, so they have fewer nonproteasome targets ([@B135]).

### 3. Epoxomicin and Epoxyketones {#s18}

Another naturally derived proteasome inhibitor is epoxomicin, an actinomycete fermentation metabolite. It is a modified peptide that contains a C-terminal *α*′,*β*′-epoxyketone group attached to an aliphatic P1 amino acid ([@B135]). Epoxomicin is extremely specific for the proteasome. The crystal structure of the yeast 20S proteasome in complex with epoxomicin revealed its unusual mechanism of action and explained the basis for proteasome specificity ([@B99]). Epoxomicin reacts covalently with both the catalytically active N-terminal threonine hydroxyl and the free amino group, producing a highly stable and irreversible morpholino ring ([@B99]). Unlike other proteasome inhibitors that only form a bond with the threonine hydroxyl, the double covalent bond formation of the epoxyketone group limits its reactivity to the N-terminal nucleophile threonine proteases without inhibiting any other cellular protease ([@B102]). Since the discovery of epoxomicin as a proteasome inhibitor, many *α*′,*β*′ epoxyketone electrophiles have been incorporated into peptide sequences and optimized for binding to the proteasome *β* subunits. The most well characterized epoxyketone inhibitor is carfilzomib (Kyprolis; Onyx Pharmaceuticals/Takeda, South San Francisco, CA) ([Fig. 4A](#F4){ref-type="fig"}), a second-generation, FDA-approved proteasome inhibitor for treatment of RRMM (discussed further in section V).

### 4. Lactacystin and β-Lactone {#s19}

Lactacystin, a *Streptomyces* metabolite, is a nonpeptide proteasome inhibitor. Lactacystin itself does not inhibit the proteasome, but at neutral pH lactacystin spontaneously converts to clasto-lactacystin-*β*-lactone, which is reactive with the proteasome. The *β*-lactone reacts with the proteasome active site threonine, resulting in opening of the *β*-lactone ring and acylation of the proteasome catalytic threonine hydroxyl ([@B102]). The yeast 20S proteasome in complex with the lactacystin crystal structure confirmed this mechanism, providing strong evidence that an acyl enzyme conjugate is an intermediate in proteasome catalysis ([@B102]). Lactacystin is more proteasome specific than MG-132, with a single off-target substrate (cathepsin A). Although lactacystin is considered an irreversible proteasome inhibitor, its adduct is slowly water hydrolyzed (half-life of approximately 20 hours). Lactacystin is the least stable of the proteasome inhibitors and exists in vivo in equilibrium with lactathione, its glutathione reaction product ([@B135]). Despite this drawback, the high proteasome selectivity makes lactacystin a viable proteasome inhibitor for investigating the role of the proteasome in cellular processes.

### 5. Vinyl Sulfones {#s20}

Peptide vinyl sulfones are a class of irreversible proteasome inhibitors. Peptide vinyl sulfones also inhibit cysteine proteases (e.g., cathepsins), but changing the functional groups in the inhibitor's peptide portion can modulate their specificity ([@B213]). For example, replacing the benzyloxycarbonyl (*Z*) group with the 3-nitro-4-hydroxy-5-iodophenylacetate group in ZLVS (*Z*-Leu3-VS) generates NLVS, significantly reducing inhibition of cathepsins B and S ([@B135]). Peptide vinyl sulfones are easy and inexpensive to synthesize, and their irreversible binding makes them attractive as protease activity probes. Peptide vinyl sulfones are commonly labeled with fluorophores, biotin, or a radioactive moiety, and specific uses as proteasome activity probes are discussed in section IV. Interestingly, vinyl sulfones are more potent and more trypsin-like site--selective inhibitors than epoxyketones with an identical peptide sequence ([@B142]), a feature exploited in the development of *β*2-specific proteasome inhibitors, as discussed in section V.

C. Considerations for Proteasome Inhibitor Design {#s21}
-------------------------------------------------

In this section, we review the structural features that have been exploited to design specific inhibitors of the 20S catalytic sites.

### 1. Substrate Binding Pockets {#s22}

All six proteasome catalytic subunits (constitutive and immune) have a similar substrate binding site topology, in which the S1 position is buried in the subunit next to the threonine, the S2 is solvent exposed, and both the catalytic subunit and its neighbor contribute to the S3 binding position ([@B101]) ([Fig. 4B](#F4){ref-type="fig"}). However, residues that make up the S1 and S3 sites have very different catalytic subunit properties. Modification of the P1 and P3 sites on a proteasome inhibitor can significantly alter their subunit specificity and affinity. *β*5c prefers a small hydrophobic group in P1 and a large hydrophobic group in P3, whereas *β*5i favors the inverse arrangement ([@B102]). Therefore, altering the hydrophobic group size in P1 and P3 confers selectivity for *β*5c or *β*5i. Due to solvent exposure in the P2 position, P2 can accommodate a range of moieties without affecting proteasome binding and is often the site for modifications aimed at improving inhibitor solubility and stability. P2 is also a useful attachment site for fluorescent probes, biotin tags, or azide handles (discussed further below).

### 2. Structural Analysis of Bound Inhibitors {#s23}

Knowledge of protein structure and its interaction with ligands guides drug discovery and design. X-ray crystallography is an excellent method for obtaining high-resolution proteasome structures in complex with inhibitors and has been instrumental in understanding proteasome function and advancing proteasome inhibitor development ([@B32]). The early structures of ALLN- and lactacystin-bound proteasomes provided clues as to the threonine catalytic mechanism and intermediate states ([@B32]). The structures of a substrate analog-bound proteasome showed long-range allosteric changes that occur upon substrate binding in the active site. The inhibitor-bound structure can be used together with biochemical data for structure-activity relationship studies and subsequent lead compound optimization.

There are drawbacks to using crystallography to study proteasome inhibitor--proteasome interactions. First, solvent conditions and inhibitor concentrations used in cocrystallization are not physiologic and should be considered when interpreting the resultant structure. 20S proteasome crystals are usually soaked in solutions with high inhibitor concentrations under conditions that preserve crystal integrity, whereas enzymatic assays are carried out at 37°C with low inhibitor concentrations and proteasomes under conditions optimized for substrate degradation. Discordant data in the yeast 20S proteasome structure in complex with ALLN showed that the inhibitor bound to all six proteasome active sites, but the biochemical data indicated that the ALLN proteasome inhibitor preferentially inhibited the *β*5 site (with very low activity against *β*1 and *β*2) unless used at extremely high concentrations ([@B102]). If one considers that most proteasome inhibitors affect multiple active sites at high concentrations and that proteasome inhibitor concentration in the crystallization condition was in the millimolar range, it is unsurprising that the inhibitor bound all sites. This example illustrates the need to carefully consider existing biochemical data when interpreting new structures.

In addition, obtaining good diffraction data relies on homogenous crystal packing. Under these conditions, one may miss larger-scale conformational changes that take place upon 20S proteasome ligand binding. The inherent drawbacks in crystallography methodology highlight the need to incorporate other structural methods into understanding the proteasome. Recent advances in cryo-electron microscopy (EM) and single particle analysis make it possible to obtain near atomic level--resolution protein structures in more physiologic conditions ([@B59]). Proof of principle for the cryo-EM utility in structure-based drug discovery and development is found in [@B171]. Recently, the noncovalent reversible asparagine-ethylenediamine (AsnEDA)-based, inhibitor-bound human immunoproteasome cryo-EM structure was used in structure-activity relationship studies ([@B271]). Exploiting *β*5c/*β*5i residue differences near the S1 pocket improved PKS21187 (AsnEDA-based inhibitor) affinity for *β*5i down to 15 nM (from 58 nM) and successfully improved selectivity (20-fold) over *β*5c (Santos et al., 2017). Although cryo-EM typically cannot provide quite the same resolution as crystallography, the 20S core particle characteristically has high local resolution (approximately 3 Å, in both of the above studies) at the interior of the *β* subunits, making this a valuable method for investigating proteasome ligand binding under relatively physiologic conditions.

It is important to keep in mind that cryo-EM structures are derived from averaging classes of particles, meaning that protein subconformations may be overlooked. This is important in interpreting 26S proteasome structures because the complex undergoes large-scale conformational changes during cycles of substrate binding and ATP hydrolysis, resulting in many conformational states coexisting simultaneously. Despite physiologically relevant conditions, conformer subpopulations may not be apparent. For example, Baumeister and colleagues published 26S proteasome in the ATP-hydrolyzing state ([@B21]) and the adenosine 5′-\[*γ*-thio\]-triphosphate--bound cryo-EM structures ([@B219]). However, when they performed a deep classification of more than 3 million 26S proteasome particles in the presence of both ATP and adenosine 5′-\[*γ*-thio\]-triphosphate, they identified a third state of the 26S proteasome that was believed to be an intermediate conformation during the ATP hydrolysis cycle ([@B238]). Additional intermediate 26S conformation states have been identified in humans and yeast using cryo-EM ([@B44]; [@B252]; [@B106]).

### 3. Proteasome Inhibitor Pharmacophore Properties {#s24}

As previously discussed, pharmacophores confer specific proteasome inhibitor properties, including compound stability, off-target protease inhibition, and inhibition kinetics. Interestingly, the pharmacophore nature is suggested to influence proteasome inhibitor active site specificity. Epoxyketone warhead replacement with vinyl sulfone moieties in *β*5 inhibitors further improves *β*5 site (but not *β*5i site) selectivity ([@B213]). Therefore, each warhead confers unique properties to the proteasome inhibitor; thus, selecting a pharmacophore along with the appropriate controls requires careful consideration.

IV. Methods for Pharmacological Proteasome Research {#s25}
===================================================

Extensive methodology exists for investigating proteasome function in vitro and in vivo. Here, we describe some commonly used methods for proteasome purification, peptidase activity assays, and protein degradation assays in vitro and in cell culture, and we discuss their advantages and limitations.

A. Proteasome Purifications {#s26}
---------------------------

Rigorous and reproducible studies of proteasome pharmacology require a source of pure and active proteasomes. The following is a summary of methods for endogenous and affinity-tagged proteasome purifications.

### 1. Endogenous Proteasome Purification {#s27}

Endogenous proteasomes are purified from a variety of tissues using a series of anion exchange chromatography columns ([@B136]; [@B223]). After purification, 20S and 26S proteasomes are separated by gel filtration or glycerol gradient centrifugation. Because 26S proteasomes require ATP binding to remain intact, omitting ATP from the homogenization and chromatography buffers enriches for 20S proteasomes. Rabbit skeletal muscle and bovine liver have abundant proteasomes, making it possible to obtain mostly pure proteasomes (\>95%) in milligram quantities in under a week with anion exchange chromatography.

Another method to purify endogenous 26S proteasomes from almost any tissue or cell type takes advantage of the 19S regulatory particle's affinity for proteins containing UBL domains ([@B28]). Recombinant glutathione *S*-transferase (GST) fused to the RAD23B UBL domain, a ubiquitin shuttling factor, is purified from *Escherichia coli* and bound to glutathione beads. 26S proteasomes in cell or tissue lysates bind the GST-UBL column while all other cellular proteins are washed away. Bound 26S proteasomes are subsequently eluted with high concentrations of a tandem ubiquitin-interacting motif derived from Rpn10, a 19S ubiquitin binding subunit ([@B28]). Unlike anion exchange chromatography (which takes approximately 3 days), the UBL-affinity method takes a single day and does not use high-salt buffers. This rapid and gentle 26S purification is essential to retain loosely associated proteasome proteins that are lost during anion exchange chromatography.

Because the GST-UBL bait occupies UBL binding sites on 19S, endogenous UBL domain-containing proteins and ubiquitin conjugates may be dislodged from the proteasome upon purification ([@B144]). Despite this limitation, the UBL-affinity method has been valuable in studies investigating 26S proteasome composition in a variety of physiologic and disease states. For example, [@B190] used the UBL-affinity method to identify Rpn13, a novel human 19S subunit that tethers and activates UCHL5 (a DUB) to the 26S proteasome and functions as a ubiquitin receptor ([@B121]). The UBL-affinity method also copurifies other important proteasome-associated proteins with important roles in regulating proteasome function and ubiquitin-conjugate degradation (e.g., the DUB USP14) ([@B144]). A significant advantage of the UBL-affinity method is that one can purify proteasomes from diseased tissues and study the changes in proteasome activity and composition without genetic alterations.

Most commercially available 20S and 26S proteasomes are purified from mammalian (e.g., human, rabbit) erythrocytes. Since erythrocytes lack nuclei, these endogenous proteasomes are "aged," perhaps with oxidative damage, and may have lower basal activity and poorer gating function than those derived from nucleated cells.

### 2. Affinity-Tagged Proteasomes {#s28}

Several groups have created human cell lines and yeast strains stably expressing affinity-tagged proteasome subunits to rapidly isolate proteasomes for structural and functional studies. Affinity tags are often appended to the Rpn11 or *β*4 C termini because modifications on these subunits do not effect proteasome function in cellular or yeast cultures.

Affinity-tagged proteasome purifications are especially useful for studying changes in 26S proteasome composition because they typically copurify with more ubiquitin conjugates and proteasome-interacting proteins than other methods. For example, [@B149] used a tobacco etch virus (TEV) protease--cleavable, protein A--derived tag on Rpn11, Rpt1, and *β*4 to study proteasome-interacting protein regulation of yeast 26S complex stability. The high purity and yield of affinity-tagged proteasomes is well suited for cryo-EM studies. For example, [@B164] used cryo-EM analysis of Rpn11-3xFLAG yeast proteasomes to study the conformational dynamics during 26S substrate engagement. Affinity tags are also amenable to high purification efficiency of crosslinked complexes under fully denaturing conditions. [@B104] designed a tandem affinity tag consisting of a hexahistidine sequence followed by an in vivo biotinylation signal, termed HB. Tandem affinity purification of Rpn11-HB proteasomes after in vivo crosslinking combined with tandem mass spectrometry and quantitative stable isotope labeling of amino acids in cell culture enabled global mapping of the 26S proteasome interaction network in yeast ([@B104]). A TEV-cleavable version of the HB tag (HTBH and HBTH) allows for one-step purification of human 26S proteasomes. [@B251] generated several stable human embryonic kidney 293 (HEK293) cell lines expressing tagged subunits (e.g., Rpn11-HTBH, HBTH-Rpn1, HBTH-Rpt6). Utilizing these cell lines with in vivo and in vitro crosslinking mass spectrometry workflows and cryo-EM approaches allows comprehensive examination of protein--protein interactions within the 26S proteasome ([@B251]). [@B48] developed stable *β*4-HTBH/*α*3-FLAG and *β*4-HTBH/*α*3ΔN-FLAG HEK293 cell lines. The *α*3 N-terminal deletion (*α*3ΔN) results in a constitutively open gate. These cell lines are a tool for investigating the role of dynamic proteasome gating and are discussed further in section VI. It is worth noting that these cell lines stably express the tagged subunit in addition to the endogenous gene; thus, purification does not isolate all proteasome complexes and may not reflect all changes in proteasome composition under different physiologic states or drug treatments.

### 3. Immunoproteasomes {#s29}

Immunoproteasome preparations are usually purified from spleens and cell cultures, treated with IFN-*γ*, to increase immunoproteasome subunit expression. Immunoproteasomes can be purified using the same anion exchange chromatography methods as described above for constitutive proteasomes. However, constitutive proteasomes are ubiquitously present in all tissue types and even low amounts can interfere with immunoproteasome-specific research. [@B66] report that hydrophobic interaction chromatography can successfully separate immunoproteasomes from residual constitutive proteasome contamination after purification.

### 4. Validating and Storing Proteasome Preparations {#s30}

It is imperative to check for contaminating proteases in all proteasome preparations. For example, proteasomes can copurify with tripeptidyl-protease II (TPP-II) during anion exchange chromatography. TPP-II is a serine protease capable of cleaving the peptide substrates used in proteasome activity assays; thus, TPP-II peptidase activity should not be confused with that of the proteasome. Proteasome-specific activity can be confirmed with proteasome inhibitors as a negative control.

Regardless of the purification method, it is necessary to confirm the 20S/26S proteasome assemblies after preparation. For example, purifying affinity-tagged RPN11 proteasomes will select for single-capped 20S, double-capped 20S, and free 19S particles, whereas affinity-tagged 20S subunits select for free 20S, 26S, and 20S associated with other regulators (e.g., PA28, PA200). 20S proteasomes and 20S bound to regulators are clearly separated by native PAGE (e.g., NuPAGE 3%--8% Tris-Acetate Gel; Thermo Fisher Scientific, Waltham, MA) ([@B28]). Electrophoresis with 26S proteasomes is performed with adequate ATP and MgCl~2~ in the buffer to prevent complex dissociation and kept at 4°C ([Table 2](#T2){ref-type="table"}). After electrophoresis, peptidase activity of proteasome complexes is measured by an in-gel fluorescence activity assay ([@B28]). The gel is incubated at 37°C in buffer containing the fluorogenic peptide substrate succinyl-leucine-leucine-valine-tyrosine (Suc-LLVY)-7--amino‐4‐methylcoumarin (amc) and the cleaved amc fluorophore is visualized with UV light. The addition of 0.02% SDS to the gel incubation buffer enhances 20S peptidase activity and improves visualization of the 20S band. After UV imaging, the gel can be processed with Coomassie or silver stain, analyzed by two-dimensional native SDS-PAGE, or transferred to a membrane for immunoblot analysis. Due to the large size of the proteasome complexes (700 kDa to 2.4 MDa), incubating the gel in SDS buffer prior to transfer may improve transfer efficiency and increase epitope availability. [@B200] provide methods for various downstream analyses to investigate the activity and composition of proteasome complexes separated by native PAGE.

The association between 19S and 20S is labile and sensitive to changes in temperature and nucleotide presence. To maintain 26S proteasome complex integrity, purification should be performed as rapidly as possible in the presence of adequate ATP and MgCl~2~ and kept at 4°C to prevent the hydrolysis of ATP. The addition of glycerol (approximately 10%) in purification and storage buffers stabilizes 26S complexes and 20S gate latency (i.e., gating function). After purification, 20S and 26S proteasomes are typically flash frozen in liquid nitrogen and stored at −80°C. Further freeze/thaw cycles should be avoided, as this damages the proteasome and affects its activity. It is important to thaw frozen 26S proteasomes on ice and use them immediately after thawing. Since freezing, storage conditions, and thawing can affect the labile 26S proteasome assembly, it is recommended that one verify 26S proteasome complexes after thawing with native PAGE.

B. Monitoring Proteasome Activity {#s31}
---------------------------------

There are numerous methods for monitoring proteasome activity in vitro and in vivo. In vitro experiments are performed with either peptide- or protein-based model substrates. The following section covers commonly used peptide- and protein-based model proteasome substrates and methods for monitoring their degradation. Finally, we discuss artificial proteasome substrates for expression in cell culture and transgenic animals.

### 1. Peptide-Based Model Substrates {#s32}

In vitro proteasome activity is often measured using a fluorescent substrate enzyme activity assay. Peptide substrates are useful for monitoring proteasome gating and peptidase activities and are amenable to high-throughput formats. Model peptide substrates are short tri- or tetrapeptides with a C-terminal fluorophore (e.g., amc).

Amino acid sequences are designed to preferentially interact with and be degraded by specific 20S subunits ([Fig. 2B](#F2){ref-type="fig"}; [Table 1](#T1){ref-type="table"}). Common peptide substrates are Suc-LLVY-amc, *tert*-butoxycarbonyl-leucine-arginine-arginine-amc, and *N*-acetyl-norleucinal-proline-norleucinal-aspartate-amc for *β*5 chymotrypsin-like, *β*2 trypsin-like, and *β*1 caspase-like activities, respectively.

###### 

Fluorogenic peptides

  Subunit   Preference    Substrate
  --------- ------------- ---------------------------------------------------
  *β*1      Acidic        Ac-nLPnLD-amc
                          *Z*-LLE-amc
  *β1i*     Hydrophobic   Ac-PAL-amc[*^a^*](#t1n1){ref-type="table-fn"}
  *β*2      Basic         Boc-LRR-amc
                          Ac-RLR-amc
  *β*2i     Basic         Not applicable[*^b^*](#t1n2){ref-type="table-fn"}
  *β*5      Hydrophobic   Suc-LLVY-amc
                          Ac-WLA-amc
  *β5i*     Hydrophobic   Ac-ANW-amc[*^a^*](#t1n1){ref-type="table-fn"}

Ac-nLPnLD-aminoluciferin, *N*-acetyl-norleucinal-proline-norleucinal-aspartate-amc; Boc-LRR, *tert*-butoxycarbonyl-leucine-arginine-arginine.

These substrates differentiate between *β*5 and *β*5i activity.

Substrates specific for *β*2i have not been developed to date.

When the amc moiety is covalently attached to the peptide, its fluorescence (excitation, 380 nm; emission, 460 nm) is greatly decreased compared with free amc. Proteolytic cleavage releases amc from the peptide and the resulting increase in fluorescence intensity is directly proportional to proteasome proteolytic activity. Fluorescence intensity is monitored in real time with a microplate reader and the rate of cleavage is determined from the slope of the reaction progress curve. This assay is rapid and suitable for high-throughput studies. Cell-based reagent kits use similar aminoluciferin-fused peptide substrates, which allows proteasome peptidase activity measurement in intact cells.

Although fluorescent substrate peptides are an excellent tool for preliminary studies measuring proteasome activity (e.g., screening compound libraries), there are several pitfalls ([Table 2](#T2){ref-type="table"}). Foremost, small peptides bypass the need for 19S recognition and unfolding and thus only report 20S peptidase activities. Therefore, changes in peptide degradation do not necessarily translate into changes in protein degradation. Importantly, at high peptide substrate concentrations, multiple active site types can participate in peptide cleavage. As such, chymotrypsin-like (*β*5) activity (Suc-LLVY-amc) assays evaluating response to a proteasome inhibitor may overestimate the reduction in protein degradation in vivo. Therefore, multiple substrate types may be required to evaluate experimental changes in proteasome activity, as various proteasomal forms (compositions) will elicit different activities to the different types of substrates.

###### 

Experimental pitfalls

  Experimental variables   Pitfall
  ------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Buffer                   
   ATP and magnesium       Stability of the 26S complex is dependent on a high ATP/ADP ratio. For monitoring 26S activity, an adequate amount of ATP and MgCl~2~ in a 1:5 ratio (we typically use 2 and 10 mM, respectively) should be present in all buffers to maintain the stability of the 26S proteasome complex. At the same time, the levels of ADP should be kept at a minimum
   Glycerol                Glycerol in the buffer stabilizes and maintains the closed, latent gate. Typically, purification buffers for proteasomes contain 10% glycerol, and assay buffers contain 5%
   SDS                     Addition of 0.02% SDS to assay buffer mildly stimulates opening of the latent 20S gate
  Proteasome population    Proteasomes are present as individual 20S particles and 26S particles (singly caped 20S-19S and doubly capped 19S-20S-19S). The 26S complex can dissociate into the 19S and 20S constituents over time, after a freeze/thaw, or in response to buffer condition changes
                           When performing experiments with purified 26S proteasomes, it is important to determine the ratio of intact 26S and free 20S proteasomes. This is commonly accomplished by native PAGE electrophoresis as described in the text
  Microplate               The type of microplate (e.g., untreated vs. nonbinding surface treatments, polypropylene vs. polystyrene) can affect the observed activity. Some substrates (e.g., GFP) interact with and "stick" to untreated plate surfaces. Some compounds or small substrates may bind to the plate surface and reduce the effective concentration in the assay. It is worthwhile to confirm results with new compounds or substrates by using two or more types of plates. Bovine serum albumin can be included in the buffer to prevent nonspecific binding to the plate
  Proteasome gating        Experiments probing the role/regulation of the proteasome gate might be facilitated by using the "open-gate" 20S mutant, *α*3ΔN
                           Suc-LLVY-amc has been shown to mildly stimulate gate opening, so another substrate (e.g., Ac-nLPnLD-amc) should be used in conjunction

### 2. Protein-Based Model Substrates {#s33}

Many protein substrates are available to monitor 20S and 26S proteasome degradation in vitro (e.g., using purified proteasomes or cellular lysates). Here we describe methods for quantitating protein degradation and give examples of model substrates for 20S and 26S proteasome activity.

#### a. Methods to quantitate protein degradation {#s34}

The extent of in vitro protein degradation can be measured in several ways. The fluorescamine assay is a quantitative method for measuring protein cleavage products generated by the proteasome. The proteasome processively degrades proteins and the generated products are equivalent to the number of substrate molecules degraded multiplied by the mean number of cuts made in a single polypeptide ([@B134]). Fluorescamine addition to an amine free assay buffer quickly labels new N-terminal amines on proteolytically cleaved short peptides.

Alternatively, the proteins can be separated by SDS-PAGE and monitored for substrate band disappearance via Coomassie or silver staining or immunoblot analysis. Care must be taken when monitoring degradation via Western blot analysis, as degradation of the epitope results in complete loss of signal, which may not correlate with complete protein degradation. Since most gel-based protein degradation assays are performed with small reaction volumes (\<20 *µ*l) incubated in centrifuge tubes, the amount of substrate remaining should be normalized to a loading control (e.g., a 20S proteasome subunit) to control for loss of substrate protein during pipetting or incubation steps. Fluorescence anisotropy is useful to follow 20S and 26S proteasome degradation of fluorescent dye--labeled protein substrates in real time ([@B29]; [@B233]). [@B218] describe methods for high-throughput measurement of 26S ubiquitin-dependent degradation using dye-labeled substrates.

#### b. 20S (19S-independent) substrates {#s35}

Intrinsically disordered proteins are unstructured, thus abrogating the requirement for the unfoldase activity associated with the 19S regulatory particle. *β*-casein is a good substrate for monitoring 20S protein degradation and is commercially available. One should use aggregation-prone proteins (e.g., *α*-synuclein) with caution, since soluble oligomers can impair proteasome function ([@B233]).

#### c. 26S (ubiquitin-independent) substrates {#s36}

Folded substrates are required to determine the 19S contribution toward 26S proteasome degradation. Ornithine decarboxylase (ODC) is a stably folded protein containing a C-terminal degradation tag ([@B90]) that promotes rapid ubiquitin-independent degradation by 26S proteasomes ([@B173]). Fusing the ODC degradation tag (cODC) to other proteins promotes their proteasomal degradation ([@B120]). For example, cODC fusion to the titin I27 domain allows for ubiquitin-independent degradation of a folded protein, although the kinetics may be slow ([@B110]). Destabilizing mutations can be introduced to I27 and accelerate substrate degradation ([@B110]).

#### d. 26S (ubiquitin-dependent) substrates {#s37}

The 26S ubiquitin-dependent degradation of folded proteins can be monitored with a tetra-ubiquitin fused green fluorescent protein (GFP) ([@B161]; [@B218]) with a C-terminal unstructured region ([@B188]) or a tetra-ubiquitinated dihydrofolate reductase ([@B234]). It is also possible to express some cODC fusion proteins in vivo to monitor proteasome activity.

### *3. Proteasome Activity in Cell Culture* {#s38}

The 26S proteasome degrades ubiquitinated proteins and proteasome impairment leads to polyubiquitinated protein accumulation. Measuring changes in high molecular weight polyubiquitin protein conjugates via immunodetection is used to monitor changes in proteasome activity. This is a general, nonspecific method to measure changes in proteasome degradation and should not be used in isolation to assess proteasome activity.

Stable GFP-fusion reporter expression is commonly used in cell culture to monitor proteasome activity. Measuring fluorescent reporters is a well-established technique for monitoring proteasome activity. Changes in reporter protein levels (in the absence of translation changes) inversely reflect UPS degradative capacity. Wild-type GFP has a long half-life in mammalian cells and therefore is not a suitable proteasome degradation substrate for most experiments. Several GFP fusion proteins have been engineered as specific proteasome substrates ([Table 3](#T3){ref-type="table"}). [@B26] designed a synthetic reporter consisting of a short degron CL1, a consensus ubiquitination signal sequence first identified in fission yeast ([@B91]), fused to the C terminus of GFP (GFP^u^), thereby targeting it for ubiquitin-dependent proteasome degradation. CL1 degron addition converted the GFP half-life from approximately 10 hours to 30 minutes. Cell compartment--specific proteasome function can be monitored by localization of GFP^u^ directed to the nucleus (nuclear localization signal-GFP^u^), the cytoplasm (nuclear export signal-GFP^u^) ([@B25]; [@B27]), or neuronal synapses (postsynaptic density 95-GFP^u^ and synaptosomal-associated protein 25-GFP^u^) ([@B250]) ([Table 3](#T3){ref-type="table"}).

###### 

Cellular proteasome substrates

  Substrate          Ub/Pathway       Localization   *t*~1/2~   Reference
  ------------------ ---------------- -------------- ---------- -----------
  GFP^u^             Yes/CL1 degron                  30 min     [@B26]
   NLS-GFP^u^        Yes/CL1 degron   Nuclear        60 min     [@B27]
   NES-GFP^u^        Yes/CL1 degron   Cytosolic      60 min     [@B27]
   PSD95-GFP^u^      Yes/CL1 degron   Postsynaptic   ND         [@B250]
   SNAP25-GFP^u^     Yes/CL1 degron   Presynaptic    ND         [@B250]
  TCR-*α*--GFP       Yes/ERAD                        ND         [@B67]
  Ub-M-GFP           Yes/"normal"                    "Stable"   [@B60]
  Ub-R-GFP           Yes/N-end rule                  "Short"    [@B60]
  Ub^G76V^-GFP       Yes/UFD                         "Short"    [@B60]
  Ub^G76V^-dendra2   Yes/UFD                         ND         [@B108]
  GFP-ODC            No                              2 h        [@B270]

M, methionine; ND, not determined; NES, nuclear export signal; NLS, nuclear localization signal; PSD95, postsynaptic density 95; R, arginine; SNAP25, synaptosomal-associated protein 25; *t*~1/2~, in vivo half-life; TCR-*α*, T-cell receptor *α* chain.

Other UPS reporters have been generated to determine targeted proteasome degradation using different pathways. The N-end rule relates the cellular protein half-life to the identity of its N-terminal residue ([@B243]). Fluorescent substrates of the N-end rule degradation pathway have been created with ubiquitin-GFP fusion constructs. When these ubiquitin fusion proteins are expressed in cells, DUBs rapidly cleave the ubiquitin and expose an unmodified N-terminal GFP residue. N-terminal arginine residue exposure (e.g., the substrate ubiquitin-R-GFP) recruits ubiquitin recognin box UBR domain E3 ligases that ubiquitinate the protein, targeting it for proteasome degradation ([@B60]). Techniques for generating ubiquitin fusion proteins with varying half-lives and conditional mutants are described in [@B76] and [@B242]. Unlike ubiquitin-R-GFP, the reporter Ub^G76V^-GFP cannot be deubiquitinated (thereby bypassing the N-end rule pathway) and is a model substrate for the in vivo ubiquitin fusion degradation (UFD) pathway ([@B60]). The T-cell receptor protein *α* chain is rapidly degraded in nonhematopoietic cells, and a T-cell receptor protein *α*--GFP fusion protein can monitor ERAD-specific proteasome activity ([@B67]). Protein synthesis also influences the steady-state protein levels, and synthesis rates can be affected by cellular stress and transfection efficiency and vary from cell to cell. Therefore, it is imperative to use appropriate experimental design to take expression and translation differences into account when monitoring protein degradation. Commonly used methods are pulse-chase experiments ([@B215]), cycloheximide chase experiments ([@B49]), bicistronic expression vectors ([@B38]), and measurement of stable long-lived proteins ([@B134]). Finally, each substrate only illustrates a single degradation pathway, which may or may not accurately reflect all UPS perturbations within a cell. It is advantageous to consider the use of multiple proteasome substrates to confirm findings.

In addition to cellular proteasomal activity, proteasome localization and dynamics can also be monitored with fluorescently labeled proteasome subunits. Both *α* and *β* subunits can be fused to a fluorescent protein and have been shown to efficiently incorporate into proteasome particles. For example, *α*4-yellow fluorescent protein ([@B179]) and a cyan fluorescent protein--tagged *β*1i ([@B195]) have been used to monitor localization dynamics of constitutive and immunoproteasomes in living cells. Detailed methods for monitoring proteasome dynamics in living cells are described elsewhere ([@B103]).

### *4. In Vivo Proteasome Activity* {#s39}

Transgenic animals that carry UFD proteasome substrates have also been generated and are used to study proteasome function in live tissues ([@B156]; [@B159]). Detailed methods for monitoring UFD protein degradation in yeast, cell lines, and transgenic mice are described in [@B169]. The photoactivatable Ub^G76V^-dendra2 construct monitors proteasome activity independent of translation and has been successfully used in transgenic *Caenorhabditis elegans* to determine tissue-specific proteasome degradation rates ([@B108]).

C. Proteasome Active Site Probes {#s40}
--------------------------------

Activity-based probes (ABPs) recognize catalytic sites on the constitutive or immunoproteasomes without requiring genetic techniques. Most proteasome ABPs are modified proteasome inhibitors with a fluorescent molecule incorporated at or near the N terminus. ABPs have been developed that can distinguish specific constitutive and immunoproteasome subunits ([@B115]). After proteasome labeling and SDS-PAGE protein separation, the modified proteasome subunits are immediately visualized via in-gel fluorescence or immunoblotting. Furthermore, cell-permeable ABPs are compatible with live-cell imaging to detect real-time proteasome localization or with flow cytometry--based experiments. Site-selective ABPs are useful in determining novel proteasome inhibitor subunit specificity. A recent review ([@B115]) provides a detailed account of currently available APBs.

V. Proteasome Inhibitors to Treat Human Disease {#s41}
===============================================

A. Hematologic Malignancies {#s42}
---------------------------

### 1. Bortezomib and Multiple Myeloma {#s43}

At therapeutic doses, bortezomib inhibits approximately 30% of proteasome-mediated protein degradation ([@B2]), which is sufficient to induce MM tumor cell apoptosis without causing general toxicity in nontransformed cells. Considering the indispensable role of proteasome function in all cell types, this raises an important question: why is bortezomib particularly toxic to MM cells? First, proteasome inhibition stabilizes the NF-*κ*B complex in the cytoplasm and reduces NF-*κ*B--dependent gene expression. MM cells have increased NF-*κ*B activity and rely on this pathway for survival and proliferation ([@B117]). Furthermore, NF-*κ*B activity generates more proinflammatory NF-*κ*B activators in a positive feedback loop; therefore, partial proteasome inhibition is sufficient to reduce this pathologic cascade ([@B4]). Bortezomib-mediated NF-*κ*B inhibition enhances the effects of anti-MM conventional chemotherapeutic agents (e.g., dexamethasone, lenalidomide) and increases progression-free survival and overall survival for patients with MM ([@B96]). Second, proteasome inhibition reduces misfolded protein clearance. MM arises from mature Ig-secreting plasma cell hyperproliferation in the bone marrow and MM cells have a high rate of Ig production. Igs are large multisubunit molecules synthesized and folded in the ER, where they are post-translationally modified prior to secretion. The high Ig production rate and multiple modifications make MM cells heavily reliant on the proteasome and ERAD to maintain ER homeostasis ([@B47]); and they are more sensitive to proteasome inhibition. Accordingly, MM treatment with proteasome inhibitors results in a toxic misfolded protein buildup activating c-Jun N-terminal kinase and eventually resulting in apoptosis. Third, proteasome inhibition stabilizes various tumor suppressor proteins (e.g., p27, p53) and prevents cell cycle progression ([@B45]).

### 2. Bortezomib Resistance {#s44}

Although bortezomib revolutionized the treatment of MM, bortezomib resistance and relapse often occurs in patients who initially respond to bortezomib. Therefore, bortezomib resistance is a major issue for MM therapy. There are several mechanisms linked to bortezomib resistance and they fall into two broad categories. First, there are changes in proteasome subunit composition and expression ([@B158]). In addition, mutations in the *β*5 bortezomib binding pocket are associated with bortezomib resistance in MM cell lines ([@B176]). However, the same mutations have not been confirmed in patients with MM resistant to bortezomib treatment. Bortezomib-resistant MM cells also display transcriptome alterations including increased antiapoptotic protein and decreased proapoptotic protein expression ([@B262]). For example, bortezomib-resistant MM cells have higher Bcl-2 family ([@B220]) and heat shock protein (Hsp27, Hsp70, and Hsp90) expression, which is expected to mitigate the misfolded protein burden in these cells.

Other extrinsic factors contribute to bortezomib resistance. Not surprisingly, the bone marrow microenvironment plays an important role in supporting bortezomib resistance. Bone marrow stem cells (BMSCs) isolated from patients with bortezomib-resistance MM have different cytokine profiles than BMSCs from patients with bortezomib-sensitive MM ([@B116]). Several specific prosurvival cytokines and microRNAs are upregulated and contribute to bortezomib resistance ([@B109]). Interestingly, BMSCs from bortezomib-resistant patients confer resistance to proteasome inhibitor--naïve MM cells, whereas proteasome inhibitor--naïve MM cells cocultured with BSMCs from patients with bortezomib-sensitive MM respond to subsequent bortezomib exposure ([@B109]). The elucidation of specific microenvironment mechanisms supporting bortezomib resistance is expected to identify additional targets for combination therapies to enhance proteasome inhibitor sensitivity in patients with RRMM.

### 3. Bortezomib Dose-Limiting Toxicity {#s45}

The primary dose-limiting bortezomib treatment toxicity is peripheral neuropathy (PN). Bortezomib-induced PN typically affects the peripheral nervous system (PNS) sensory fibers and is associated with a painful burning sensation, numbness, and/or tingling in the extremities. Clinical trials report a bortezomib-induced PN incidence (all grades) between 30% and 60% ([@B129]), with grade ≥3 occurring between 2% and 23% ([@B208]). PN is a major cause of dose reduction or discontinuation among patients and overcoming this limitation is a significant challenge to clinicians and pharmaceutical developers. Recent clinical trials demonstrated that patients receiving alternative dosing schedules (i.e., once weekly, instead of biweekly) or subcutaneous injection of bortezomib (instead of intravenously) had a lower incidence of PN, without changes in efficacy. For patients with intolerable PN, these options constitute another avenue of hope before discontinuing treatment ([@B208]).

Although the exact molecular mechanisms by which bortezomib induces PN are not completely clear, clinical and experimental evidence points to pathology in the primary sensory neuron cell bodies as a major contributing factor. The PNS encompasses the nerve fibers and cell bodies that reside outside the central nervous system (CNS) (i.e., the brain and spinal cord). Sensory receptors in periphery tissues transduce physical stimuli (e.g., pain, touch, pressure, temperature) into action potentials, which are transmitted via primary sensory neurons to the CNS. The primary sensory neuron cell bodies are in the dorsal root ganglion (DRG) just outside of the spinal cord. Many in vivo mouse studies and in vitro DRG explant studies of bortezomib-induced PN demonstrate accumulation of ubiquitinated proteins in DRG soma, defects in mitochondrial calcium homeostasis, disrupted mitochondrial axonal transport, alterations in tubulin polymerization and localization, and defects in fast axonal transport due to blockage of axonal protein turnover ([@B39]; [@B61]; [@B226]).

Why are the DRG neurons especially susceptible to proteasome inhibitor toxicity? Proper CNS and PNS neuron function requires an exquisitely controlled microenvironment. To this end, the blood-neural barrier and the blood-brain barrier form a protective barrier between the changing circulatory milieu and the PNS and CNS, respectively. These intricate barriers contain complex tight junction proteins. Unlike the rest of the nervous system, the cell body-rich area within the DRG has endothelial fenestrations and lacks tight junction proteins, rendering it more permeable to substances in the blood compared with the rest of the nervous system. This region is highly vascularized and blood permeability has been observed in human subjects using magnetic resonance imaging with gadolinium contrast agents ([@B129]). Although bortezomib cannot cross the tight blood-neural barrier and blood-brain barrier, it can cross into the cell body-rich region of the DRG and inhibit proteasome function. This differential permeability is thought to underlie peripheral sensory system vulnerability to cytostatic agents used in chemotherapy (e.g., bortezomib) compared with other neurons in the CNS ([@B129]).

[@B10] suggested that bortezomib-induced neurotoxicity is due to mitochondrial serine protease, HtrA2/Omi, inhibition and independent of proteasome inhibition. They also showed that a second-generation proteasome inhibitor, carfilzomib, did not inhibit HtrA2/Omi in this study. The authors concluded that proteasome inhibitor--induced neurotoxicity is due to off-target bortezomib effects and is not generalizable to the proteasome inhibitor class. However, two subsequent independent studies failed to show bortezomib-mediated HtrA2 inhibition ([@B14]; [@B58]). Carfilzomib is associated with less severe PN than bortezomib; however, the role of HtrA2 or other off-target effects in proteasome inhibitor--induced PN remains to be determined.

### 4. Bortezomib Efficacy in Solid Tumors {#s46}

Despite bortezomib's clinical efficacy in treating hematologic malignancies, it has had limited success in clinical trials for solid tumors. This may arise from poor bortezomib tissue penetration (at the doses used in MM) and rapid clearance from the blood ([@B3]). Due to an increased risk for PN, the dosage cannot be increased to overcome poor tissue penetration. Second-generation proteasome inhibitors are in development to overcome these limitations of bortezomib. Ongoing clinical trials are evaluating combinations of chemotherapy and radiotherapy with bortezomib in a search for new synergistic drug combinations.

B. Second-Generation Proteasome Inhibitors {#s47}
------------------------------------------

Bortezomib treatment efficacy in human cancer renewed interest in developing other novel proteasome inhibitors to overcome bortezomib limitations. The FDA has approved two second-generation proteasome inhibitors, carfilzomib (2012) and ixazomib (2015), for use in treating patients with RRMM. Carfilzomib and ixazomib are well tolerated in heavily pretreated patients and show effectiveness in bortezomib-resistant cases ([@B208]). Importantly, most cases of PN with carfilzomib and ixazomib are low grade and usually do not worsen preexisting PN resultant from previous bortezomib treatment ([@B208]). [@B208] provide a detailed review of the bortezomib, carfilzomib, and ixazomib clinical trials. Here we highlight second-generation FDA-approved proteasome inhibitors and selected newer proteasome inhibitors undergoing preclinical evaluation in hematologic cancers, solid tumors, and autoimmune disorders. Our list of proteasome inhibitors is not intended to be comprehensive but rather to increase familiarity with these important aspects. [Table 4](#T4){ref-type="table"} lists important properties of first- and second-generation proteasome inhibitors in clinical trials.

###### 

Proteasome inhibitors in clinical testing

  Inhibitor     Class         IC~50~ In Vitro Peptidase Activity   Half-Life   Route   Binding   Reference                       
  ------------- ------------- ------------------------------------ ----------- ------- --------- ----------- ------------------- -------------------------------
                              *nM*                                 *min*                                                         
  Bortezomib    Boronate      7.9                                  53          590     110       i.v./s.c.   Slowly reversible   Cauhan et al. (2005)
  Carfilzomib   Epoxyketone   6                                    2400        3600    \<30      i.v.        Irreversible        [@B266]
  Ixazomib      Boronate      3.4                                  31          3500    18        p.o.        Reversible          Cauhan et al. (2005), [@B267]
  Marizomib     *β*-lactone   3.5                                  430         28      10--15    i.v.        Irreversible        [@B265]
  Oprozomib     Epoxyketone   36 (*β*5)                            ND          ND      30--90    p.o.        Irreversible        [@B272], [@B197]
                              82 (*β*5i)                                                                                         

C-L, caspase-like activity (*β*1); CT-L, chymotrypsin-like activity (*β*5); ND, not determined; T-L, trypsin-like activity (*β*2).

### 1. Carfilzomib {#s48}

Carfilzomib is the second FDA-approved proteasome inhibitor. Carfilzomib is used as a single agent or in combination with immunomodulatory agents for patients with RRMM who have received one to three prior therapies, including other proteasome inhibitors ([@B227]). Carfilzomib has a tripeptide backbone containing phenylalanine, leucine, and homophenylalanine with a terminal epoxyketone group that forms an irreversible covalently bond with the proteasome catalytic threonine ([@B228]). As with epoxomicin, the carfilzomib epoxyketone warhead forms a dual covalent adduct with the active site threonine, which greatly reduces the off targets.

Importantly, carfilzomib provides some therapeutic benefit for patients with RRMM who relapse after bortezomib treatment, while also rendering less neurotoxic side effects ([@B227]; [@B208]). The phase III ENDEAVOR (A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma) clinical trial compared bortezomib plus dexamethasone versus carfilzomib plus dexamethasone in a cohort of patients with newly diagnosed MM. ENDEAVOR reported a significantly higher incidence of ≥2 PN in the bortezomib group (32%) versus 6% in the carfilzomib group ([@B74]). This was the first head-to-head comparison between bortezomib- and carfilzomib-treated patients. Unfortunately, drug resistance is observed after carfilzomib treatment in a small subset of patients ([@B37]). Although the resistance mechanism is not fully elucidated, studies suggest that increased expression of drug efflux pump P-glycoprotein (a known transporter of carfilzomib) in carfilzomib-resistant cells contributes to the resistant phenotype ([@B8]). However, more detailed studies are needed to confirm this resistance mechanism.

Carfilzomib also shows therapeutic promise in several preclinical models of solid tumors. Carfilzomib effectively sensitized tumor cells to doxorubicin-induced apoptosis in several in vivo preclinical solid tumor models, including neuroblastoma and colon cancer ([@B151]; [@B84]). Many doxorubicin-resistant tumor cells have upregulated NF-*κ*B activity that promotes survival ([@B80]; [@B81]), suggesting that combination treatment with a proteasome inhibitor may be effective at overcoming doxorubicin resistance. Although the exact mechanisms are unknown, it is thought that carfilzomib-mediated NF-*κ*B inhibition sensitizes tumor cells to doxorubicin. Based on these preclinical studies, carfilzomib (in combination with other chemotherapy drugs) is currently undergoing phase I and II clinical trials in advanced solid tumors, renal disease, transplant rejection, and hematologic malignancies (ClinicalTrials.gov).

### *2. Ixazomib* {#s49}

Bortezomib and carfilzomib are administered intravenously, requiring patients to visit a clinic several times over the course of their treatment. Ixazomib (MLN9708 \[4-(carboxymethyl)-2-\[(1*R*)-1-\[\[2-\[(2,5-dichlorobenzoyl)amino\]acetyl\]amino\]-3-methylbutyl\]-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid\]) (Ninlaro; Takeda Pharmaceuticals), is the first and currently only orally bioavailable proteasome inhibitor approved by the FDA for RRMM treatment ([@B170]). Ixazomib was developed through a large-scale, boron-containing proteasome inhibitor screening for compounds with physiochemical properties distinct from bortezomib. Ixazomib is a bioavailable prodrug and hydrolyses into the active metabolite MLN2238 (\[(1*R*)-1-\[\[2-\[(2,5-dichlorobenzoyl)amino\]acetyl\]amino\]-3-methylbutyl\]boronic acid) when exposed to the gastrointestinal tract and plasma and is a potent and reversible *β*5 proteasome subunit inhibitor ([@B175]).

Despite similarities, there are important distinctions between ixazomib and bortezomib. Importantly, clinical trials report a lower incidence of PN in patients treated with ixazomib compared with bortezomib, and ixazomib is effective in treating patients with bortezomib-resistant RRMM ([@B163]). In addition, ixazomib demonstrated five times higher drug distribution supported by blood volume distribution, with a blood volume distribution of 20.2 l/kg for ixazomib versus 4.3 l/kg for bortezomib ([@B175]). Ixazomib also displays antitumor efficacy in solid tumor preclinical models ([@B84]). Numerous phase I and II clinical trials are underway, evaluating ixazomib treatment in glioblastomas (GBMs), solid tumors, triple-negative breast cancer, B-cell lymphoma, lupus, metastatic bladder cancer, and lymphoma ([ClinicalTrials.gov](ClinicalTrials.gov)).

C. Additional Proteasome Inhibitors in Clinical Trials {#s50}
------------------------------------------------------

### 1. Marizomib {#s51}

Marizomib (NPI-0052 \[(1*S*,2*R*,5*R*)-2-(2-chloroethyl)-5-\[(*S*)-\[(1*S*)-cyclohex-2-en-1-yl\]-hydroxymethyl\]-1-methyl-7-oxa-4-azabicyclo\[3.2.0\]heptane-3,6-dione\]; Salinosporamide A), is a naturally occurring proteasome inhibitor isolated from the marine actinomycete *Salinispora tropica* and is under development for MM and GBM treatment ([@B78]). Marizomib is a *γ*-lactam--*β*-lactone that demonstrates unique binding and bioavailability profiles, setting it apart from other proteasome inhibitors. Its unusual binding mechanism was elucidated using biochemical and crystallography approaches. In contrast to other *β*-lactones, marizomib has unique chloroethyl and cyclohex-2-enylcarbinol substituents, giving rise to important interactions within proteasome active sites. These unique interactions are thought to be responsible for marizomib's high proteasome affinity and specificity ([@B102]).

Marizomib irreversibly inhibits *β*5 (IC~50~ of 3.5 nM) and *β*2 (IC~50~ of 28 nM) active sites, although it can inhibit *β*1 at higher concentrations (IC~50~ of 430 nM) ([@B264]). In vitro and binding competition experiments show that marizomib binds to all three subunits at clinically relevant doses ([@B264]). Unexpectedly, patients' *β*1 and *β*2 activities were not affected (in PBMCs) during the first cycle of marizomib treatment ([@B150]). After the second dose cycle, decreased peptidase was observed but only in packed whole blood samples, which contain mostly erythrocytes ([@B150]). Whether marizomib inhibits *β*1 and *β*2 activity in nucleated cells that can synthesize new proteins remains to be determined. Importantly, marizomib shows the ability to overcome bortezomib and carfilzomib resistance in a limited number of patients with RRMM ([@B150]). Additional trials investigating marizomib in combination with other chemotherapy drugs in RRMM are ongoing.

Marizomib is currently the only proteasome inhibitor in clinical trials that can permeate the blood-brain barrier, making it an attractive candidate in CNS malignancy treatment. In animal studies, marizomib distributed to the brain at 30% blood levels in rats and significantly inhibited (\>30%) baseline chymotrypsin-like proteasome activity in monkey brain tissue ([@B71]). Furthermore, marizomib treatment elicited a significant antitumor effect in a rodent intracranial malignant glioma model ([@B71]) and was well tolerated in phase I/II clinical trials for advanced and newly diagnosed GBM. Based on encouraging results from phase I and phase II marizomib trials in patients with GBM, a phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy for patients with newly diagnosed GBM ([ClinicalTrials.gov](ClinicalTrials.gov) NCT03345095) was scheduled to begin June 2018. GBM is the most common high-grade brain malignancy in adults, with a 25% 2-year survival after standard treatment ([@B241]). New therapies are critically needed for these patients.

### 2. Oprozomib {#s52}

Efforts to synthesize an orally bioavailable epoxyketone proteasome inhibitor led to the development of oprozomib \[ONX-0912 or PR-047 (*N*-\[(2*S*)-3-methoxy-1-\[\[(2*S*)-3-methoxy-1-\[\[(2*S*)-1-\[(2*R*)-2-methyloxiran-2-yl\]-1-oxo-3-phenylpropan-2-yl\]amino\]-1-oxopropan-2-yl\]amino\]-1-oxopropan-2-yl\]-2-methyl-1,3-thiazole-5-carboxamide)\]. Oprozomib is an irreversible and potent *β*5c and *β*5i proteasome subunit inhibitor, with IC~50~ values of 36 and 82 nM, respectively ([@B145]). Oprozomib oral administration demonstrated antitumor activity in MM, squamous cell carcinoma of the head and neck, and colorectal cancer preclinical models ([@B197])

The first phase I study (ClinicalTrials.gov NCT01365559) with single-agent oprozomib evaluated patients with advanced solid tumors. Oprozomib was well tolerated, with low-grade gastrointestinal side effects being the most common. Unfortunately, despite dose-dependent increases in proteasome inhibition, the best response achieved was stable disease (23% of patients) and no clinically meaningful correlates between proteasome inhibition and treatment efficacy were observed. Considering that this was a heavily pretreated patient population with advanced cancer, the lack of a therapeutic response does not necessarily reflect the potential of oprozomib to treat earlier stages or other cancers. Clinical studies investigating the efficacy of oprozomib in hematologic malignancies are ongoing. A new oral oprozomib formulation is being investigated in a phase I/II study (ClinicalTrials.gov NCT01416428), and other studies are investigating oprozomib in combination with dexamethasone and lenalidomide.

D. Immunoproteasome-Specific Proteasome Inhibitors {#s53}
--------------------------------------------------

Specifically targeting the immunoproteasome could be advantageous over currently approved proteasome inhibitors in treating certain diseases. The immunoproteasome is present at low levels in normal cells. In contrast, some cancers (including MM), inflammatory diseases, and autoimmune diseases have increased immunoproteasome subunit expression ([@B143]). It is thought that selective immunoproteasome inhibition may have less adverse effects than broadly acting proteasome inhibitors like bortezomib and carfilzomib, since certain cell populations would be preferentially affected ([@B18]).

ONX-0914 (or PR-957 \[(2*S*)-3-(4-methoxyphenyl)-*N*-\[(2*S*)-1-\[(2*R*)-2-methyloxiran-2-yl\]-1-oxo-3-phenylpropan-2-yl\]-2-\[\[(2*S*)-2-\[(2-morpholin-4-ylacetyl)amino\]propanoyl\]amino\]propanamide\]) is an irreversible epoxyketone *β*5i immunoproteasome subunit inhibitor, with minimal crossreactivity for the constitutive proteasome *β*5 subunit (*β*5c). Preclinical trials demonstrate that *β*5i inhibition with ONX-0914 attenuates disease progression in colorectal cancer ([@B157]), rheumatoid arthritis ([@B172]), and systemic lupus erythematosus animal models ([@B123]). Importantly, ONX-0914 displays low neurotoxicity without sacrificing efficacy, an effect that may be attributed to the selective *β*5i inhibition ([@B247]).

[@B125] synthesized and screened ONX-0914 analogs for *β*2i inhibition. They identified and characterized compound KZR-504 (*N*-\[(2*S*)-3-hydroxy-1-\[\[(2*S*)-1-\[(2*R*)-2-methyloxiran-2-yl\]-1-oxo-3-phenylpropan-2-yl\]amino\]-1-oxopropan-2-yl\]-6-oxo-1*H*-pyridine-2-carboxamide), a *β*2i-selective proteasome inhibitor. However, KZR-504 displayed poor membrane permeability and did not ameliorate cytokine release from stimulated splenocytes ([@B125]).

Another analog, KZR-616 \[(2*S*,3*R*)-*N*-((*S*)-3-(cyclopent-1-en-1-yl)-1-((*R*)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((*S*)-2-(2-morpholinoacetamido)propanamido)propanamide\], was well tolerated in a phase I clinical trial in healthy volunteers with minimal adverse side effects (Lickliter et al., 2017). KZR‐616 recently entered a phase Ib/II clinical trial (ClinicalTrials.gov NCT03393013) as a single-agent treatment of autoimmune‐triggered inflammation (systemic lupus erythematosus).

E. Novel Combination Therapies {#s54}
------------------------------

Anticancer drugs are often administered in combination to synergistically enhance cytotoxicity and prevent drug-resistant tumor cell population development. Several known chemotherapy resistance mechanisms result from abrogated proteasome activity. For example, NF-*κ*B activity is upregulated in solid tumors that develop chemotherapy (e.g., doxorubicin) or radiation resistance and is a driving force behind the resistant phenotype ([@B135]). Accordingly, preclinical studies with solid-tumor xenograft and cellular models show increased sensitivity to chemotherapy and/or radiation-induced apoptosis when combined with proteasome inhibitors ([@B268]). Several phase I and II clinical trials are evaluating proteasome inhibitor safety and efficacy in combination with various chemotherapy agents in recurrent or refractory advanced cancers.

*β*1 and *β*2 site upregulation has been reported in tumor cells resistant to bortezomib or carfilzomib treatment ([@B135]). LU-102 (*N*-\[1-\[4-(aminomethyl)-3-methylsulfonylphenyl\]but-3-en-2-yl\]-5-\[\[(2*S*)-2-azido-3-phenylpropanoyl\]amino\]-2-(2-methylpropyl)-4-oxooctanamide) is a peptide vinyl-sulfone *β*2-specific inhibitor ([@B137]) and alone it is toxic to MM cells, but it also synergized with *β*5 inhibitors (bortezomib and carfilzomib) to overcome proteasome inhibitor resistance in MM cell lines ([@B137]). The observed synergy between *β*5 and *β*2 inhibitors suggests that multiple site-specific proteasome inhibitor combinations may be an effective alternative in proteasome inhibitor--resistant malignancies with a reduced risk of adverse side effects.

VI. Novel Proteasome Drug Targets {#s55}
=================================

A. Deubiquitinating Enzyme Inhibitors {#s56}
-------------------------------------

With three ubiquitin receptors on the proteasome, several shuttling factors, and multiple ubiquitin chain types on substrates, the process of substrate recognition by the 26S proteasome is incredibly complex and much remains unknown. We briefly summarized the process of ubiquitin-degradation in section II; here we discuss how DUBs may be targeted to treat diseases. Detailed reviews of 26S substrate recognition and processing have already been published ([@B57]; [@B65]).

Three DUBs are associated with the 26S proteasome: Rpn11, Uch37, and Usp14. Rpn11 is the only DUB that is an integral part of the 19S regulatory particle. Positioned directly above the translocation pore, Rpn11 is a metalloprotease that removes ubiquitin chains at their attachment point (lysine) on the substrate that is committed for degradation ([@B164]). Mutations in Rpn11 that disrupt its catalytic activity stall ubiquitin substrate degradation and eventually lead to cell death ([@B245]). [@B152] recently developed capzimin, a first-in-class selective inhibitor of Rpn11. The Rpn11 active site is located within the highly conserved JAMM motif and features a catalytic Zn^2+^ ion ([@B245]). Capzimin binds the catalytic zinc ion and prevents Rpn11 activity ([@B152]). Remarkably, capzimin treatment stabilized proteasome substrates and blocked proliferation in several tumor cell lines ([@B152]). This antitumor activity suggests that Rpn11 inhibition may be an effective alternative to active site inhibition for treating malignancies.

Unlike Rpn11, Uch37 and Usp14 are only transiently associated with the 19S regulatory particle ([@B33]; [@B149]). Uch37 and Usp14 enzymes trim ubiquitin chains before the substrate is committed to degradation, which may suppress protein degradation by promoting early substrate release ([@B65]). Accordingly, loss of Usp14 homolog Ubp6 increases substrate degradation by the proteasome ([@B148]; [@B132]). Despite high affinity, Usp14 easily dissociates from 26S complexes during conventional proteasome purification techniques and should be considered when designing in vitro experiments ([@B65]).

Enhancing proteasome function has the potential to treat protein misfolding disorders, such as neurodegenerative diseases, and Usp14 inhibition may promote ubiquitin-dependent protein degradation. To this end, [@B34] developed IU-47, a potent and specific inhibitor of Usp14. Inhibition of Usp14 DUB activity by IU-47 promoted proteasome degradation of the microtubule-associated protein *τ* (implicated in the pathogenesis of Alzheimer disease) in neuronal cultures and enhanced resistance to oxidative stress ([@B34]). The implications of pharmacological proteasome activation are discussed in the following section.

B. Activation of 20S by Gate Opening {#s57}
------------------------------------

We highlighted essential functions of the proteasome required for proper neuronal functioning in section II. Then section III discussed the negative impacts of proteasome inhibition on primary sensory neurons. To bridge these concepts, we will further discuss evidence that supports the proteasome as a target for pharmacological activation to treat proteopathies.

The most common neurodegenerative diseases are characterized by an accumulation of aggregation-prone proteins concomitant with a loss of proteostasis, which results in progressive death of neurons ([@B214]; [@B201]; [@B36]). Impaired proteasome function has been implicated, as a primary cause or a secondary consequence, in the pathogenesis of many neurodegenerative diseases, including Alzheimer, Parkinson, and Huntington diseases ([@B128]; [@B167]; [@B52]; [@B178]; [@B165]).

Soluble forms of aggregated proteins, called oligomers, are implicated in the pathogenesis of most neurodegenerative diseases ([@B107]; [@B105]) and haven been shown to impair proteasome function ([@B26]; [@B155]; [@B72]; [@B41]; [@B237]; [@B70]). Our laboratory recently identified a mechanism in which soluble oligomers of different proteins from multiple neurodegenerative diseases allosterically impair the proteasome gate by a shared mechanism ([@B233]). These toxic oligomers shared a similar three-dimensional conformation recognized by the antioligomer antibody, A11 ([@B127]). The A11+ oligomers bound to the outside of the 20S cylinder and stabilized the gate in the closed conformation. However, proteasome function could be rescued by adding eight-residue HbYX peptides. The HbYX peptides allosterically opened the gate and the HbYX motif peptides overcame the oligomer inhibition and restored proteasome function ([@B233]).

A recent and popular idea for treating neurodegenerative diseases is to enhance proteasome activity to suppress toxicity and related proteotoxic pathophysiology, but to date no drugs that directly activate proteasome function are available.

Since IU-47 exerts its effect upstream of the proteasome gate, it is not expected to function in conditions in which the proteasome gate is impaired. [@B48] generated an HEK293 cell line with a stable transfection of a mutant 20S *α* subunit (*α*3∆N) that induces 20S gate opening. They showed that HEK293-*α*3∆N cells had increased degradation of proteasome substrates (including tau protein) and increased resistance to oxidative stress compared with the wild type ([@B48]). Although this serves as a proof of principle that opening the proteasome gate can clear aggregation-prone proteins and increase cell viability, it cannot be determined whether pharmacologically activating the proteasome in an already diseased state (preexisting oligomers, aggregates, and oxidative stress) can restore cellular proteostasis. Nonetheless, the elucidation of a common mechanism of proteasome inhibition is a major step toward the rational design of proteasome-activating compounds, which may be a promising route to restore proteostasis in diseases.

VII. Conclusions {#s58}
================

As a highly regulated, multicatalytic macromolecular complex, the proteasome possesses multiple drug targets to modulate its degradation capacity. Proteasome inhibitors helped early researchers study the proteasome's cellular functions. Today, three inhibitors are approved for use in the clinic to treat hematologic cancers and several more inhibitors (synthetic and naturally occurring) are in preclinical and clinical testing. Fine-tuning the pharmacological properties of proteasome inhibitors may improve their efficacy for use in solid tumors. The last decade has witnessed major progress in our understanding of 26S proteasome structure and dynamics. In the coming years, we expect development of new inhibitors and activators of nonproteolytic components of the 26S proteasome. We anticipate that proteasome activation will become a validated target to treat proteotoxic diseases.
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:   glioblastoma

GFP

:   green fluorescent protein

GST

:   glutathione *S*-transferase

HbYX

:   hydrophobic-tyrosine-any residue

HEK293

:   human embryonic kidney 293

IFN

:   interferon

IKK

:   I*κ*B kinase

KZR-616

:   (2*S*,3*R*)-*N*-((*S*)-3-(cyclopent-1-en-1-yl)-1-((*R*)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((*S*)-2-(2-morpholinoacetamido)propanamido)propanamide

LU-102

:   *N*-\[1-\[4-(aminomethyl)-3-methylsulfonylphenyl\]but-3-en-2-yl\]-5-\[\[(2*S*)-2-azido-3-phenylpropanoyl\]amino\]-2-(2-methylpropyl)-4-oxooctanamide

MG-132

:   carbobenzyl-Leu-Leu-Leu-aldehyde

MHC-I

:   major histocompatibility complex class I

MLN2238 (\[(1*R*)-1-\[\[2-\[(2

:   5-dichlorobenzoyl)amino\]acetyl\]amino\]-3-methylbutyl\]boronic acid

MLN9708

:   4-(carboxymethyl)-2-\[(1*R*)-1-\[\[2-\[(2,5-dichlorobenzoyl)amino\]acetyl\]amino\]-3-methylbutyl\]-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid

MM

:   multiple myeloma

NF-*κ*B

:   nuclear factor-*κ*B

NPI-0052

:   (1*S*,2*R*,5*R*)-2-(2-chloroethyl)-5-\[(*S*)-\[(1*S*)-cyclohex-2-en-1-yl\]-hydroxymethyl\]-1-methyl-7-oxa-4-azabicyclo\[3.2.0\]heptane-3,6-dione

ODC

:   ornithine decarboxylase

ONX-0912 (or PR-047)

:   *N*-\[(2*S*)-3-methoxy-1-\[\[(2*S*)-3-methoxy-1-\[\[(2*S*)-1-\[(2*R*)-2-methyloxiran-2-yl\]-1-oxo-3-phenylpropan-2-yl\]amino\]-1-oxopropan-2-yl\]amino\]-1-oxopropan-2-yl\]-2-methyl-1,3-thiazole-5-carboxamide

ONX-0914 (or PR-957)

:   (2*S*)-3-(4-methoxyphenyl)-*N*-\[(2*S*)-1-\[(2*R*)-2-methyloxiran-2-yl\]-1-oxo-3-phenylpropan-2-yl\]-2-\[\[(2*S*)-2-\[(2-morpholin-4-ylacetyl)amino\]propanoyl\]amino\]propanamide

PN

:   peripheral neuropathy

PNS

:   peripheral nervous system

PS-341

:   Pyz-Phe-boroLeu

RRMM

:   relapsed/refractory multiple myeloma

Suc-LLVY

:   succinyl-leucine-leucine-valine-tyrosine

TPP-II

:   tripeptidyl-protease II

UBL

:   ubiquitin-like

UFD

:   ubiquitin fusion degradation pathway

UPR

:   unfolded protein response

UPS

:   ubiquitin proteasome system
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